DNTH – dianthus therapeutics, inc. (US:NASDAQ)

News

Dianthus Therapeutics (DNTH) was upgraded by Wolfe Research to "strong-buy".
Dianthus Therapeutics (DNTH) is now covered by Wolfe Research. They set an "outperform" rating and a $98.00 price target on the stock.
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dianthus Therapeutics CFO Sells $9.5 Million in Stock [Yahoo! Finance]
How Investors May Respond To Dianthus Therapeutics (DNTH) Early “GO” Decision And FDA Backing For Claseprubart [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com